Skip to content
S8191Senate2021-2022 SessionSame asA9267

Limit Step Therapy Rules

Official title

“Requires a utilization review agent to follow certain rules when establishing a step therapy protocol”

Sponsor Neil D. BreslinSD-44+1 co-sponsorAffects Finance
Status
In Assembly Committee
Insurance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 5 of 7

In Assembly · Insurance

What's happening

This bill sets new rules requiring insurance utilization review agents to limit and streamline step therapy protocols for prescription drugs.

Why it matters

  1. Limits on step therapy protocols protect patients from unnecessary delays and risks. By prohibiting requirements such as using unapproved drugs, trying and failing multiple drugs, or repeating failed therapies, the bill ensures patients can access the treatments their doctors prescribe more quickly and safely.

  2. Patient continuity and stability are better protected. The bill prevents insurers from forcing patients to restart step therapy if they have already completed it under a previous plan or if their medication was previously approved and only lost coverage due to a formulary change. This helps avoid disruptions in effective treatment.

  3. Medical professionals’ input gains more authority. If a health care provider attests that a required drug has failed, this must be accepted as sufficient proof, reducing administrative burdens and giving greater weight to the provider’s judgment over insurer protocols.

  4. Stronger enforcement and patient recourse. The bill allows for immediate overrides of step therapy if insurers do not comply with these requirements or fail to respond in a timely manner, making it easier for patients to challenge and bypass insurance-imposed barriers to care.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Limit Step Therapy Rules

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Neil D. Breslin

Senator · Senate District 44

Chair, Insurance

1 Co-sponsor

History

  1. Referred to insurance
  2. Delivered to assembly
  3. Passed senateVote 55–6
  4. Ordered to third reading cal.1440
  5. Committee discharged and committed to rules
  6. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A9267Assembly

Limit Step Therapy Rules

In Assembly Committee · Insurance · Sponsor John T. McDonald III

Impact 7 · Significant0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8191

IN SENATE

February 1, 2022

Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law and the public health law, in relation to requiring a utilization review agent to follow certain rules when establishing a step therapy protocol

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding two new paragraphs 14 and 15 to read as follows:

(14) When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol cannot:

(i) require a prescription drug that has not been approved by the United States Food and Drug Administration for the medical condition being treated;

(ii) require an insured to try and fail on more than one drug before providing coverage to the insured for the prescribed drug;

(iii) require the use of a step therapy-required drug for longer than thirty days;

(iv) be imposed on an insured if the insured has taken the prescribed drug covered by the plan within the past three hundred sixty-five days;

(v) require a newly enrolled insured to repeat step therapy for a prescribed drug where that insured already completed step therapy for that drug under a prior plan; and

(vi) be imposed on an insured for a prescribed drug that was previously approved for coverage by a plan for a specific medical condition after the insured's plan implements a formulary change that impacts the formulary status of the prescribed drug.

(15) When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol accepts any attestation submitted by the insured's health care professional as defined in section four thousand nine hundred of this title stating that a required drug has failed as prima facie evidence that the required drug has failed.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD14433-01-2

§ 2. Subsections (c-3) and (g) of section 4903 of the insurance law, subsection (c-3) as added and subsection (g) as amended by chapter 512 of the laws of 2016, are amended to read as follows:

(c-3) Upon a determination that the step therapy protocol should be overridden, the health plan shall authorize immediate coverage for the prescription drug prescribed by the insured's treating health care professional. Any approval of a step therapy protocol override determination request shall be honored until the later of twelve months following the date of the approval or renewal of the plan.

(g) Failure by the utilization review agent to make a determination within the time periods prescribed in this section shall be deemed to be an adverse determination subject to appeal pursuant to section four thousand nine hundred four of this title, provided, however, that failure to meet such time periods for a step therapy protocol as defined in subsection (g-9) of section forty-nine hundred of this title or a step therapy protocol override determination pursuant to subsections (c-1), (c-2) and (c-3) of this section shall be deemed to be an override of the step therapy protocol. A utilization review agent's failure to comply with any of the step therapy protocol requirements required in subsections fourteen and fifteen of section four thousand nine hundred two of this title shall be considered a basis for granting an override of the step therapy protocol.

§ 3. Section 4902 of the public health law is amended by adding two new subdivisions 5 and 6 to read as follows:

5. When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol cannot:

(a) require a prescription drug that has not been approved by the United States Food and Drug Administration for the medical condition being treated;

(b) require an enrollee to try and fail on more than one drug before providing coverage to the insured for the prescribed drug;

(c) require the use of a step therapy-required drug for longer than thirty days;

(d) be imposed on an enrollee if the enrollee has taken the prescribed drug covered by the plan within the past three hundred sixty-five days;

(f) require a newly enrolled enrollee to repeat step therapy for a prescribed drug where that enrollee already completed step therapy for that drug under a prior plan; and

(g) be imposed on an enrollee for a prescribed drug that was previously approved for coverage by a plan for a specific medical condition after the enrollee's plan implements a formulary change that impacts the formulary status of the prescribed drug.

6. When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol accepts any attestation submitted by the enrollee's health care professional as defined in section fortynine hundred of this title stating that a required drug has failed as prima facie evidence that the required drug has failed.

§ 4. Subdivisions 3-c and 7 of section 4903 of the public health law, subdivision 3-c as added and subdivision 7 as amended by chapter 512 of the laws of 2016, are amended to read as follows:

3-c. Upon a determination that the step therapy protocol should be overridden, the health plan shall authorize immediate coverage for the prescription drug or drugs prescribed by the enrollee's treating health care professional. Any approval of a step therapy protocol override determination request shall be honored until the later of twelve months following the date of the approval or renewal of the plan.

7. Failure by the utilization review agent to make a determination within the time periods prescribed in this section shall be deemed to be an adverse determination subject to appeal pursuant to section fortynine hundred four of this title, provided, however, that failure to meet such time periods for a step therapy protocol as defined in subdivision seven-f-three of section forty-nine hundred of this title or a step therapy protocol override determination pursuant to subdivisions three-a, three-b and three-c of this section shall be deemed to be an override of the step therapy protocol. A utilization review agent's failure to comply with any of the step therapy protocol requirements required in subdivisions five and six of section forty-nine hundred two of this title shall be considered a basis for granting an override of the step therapy protocol.

§ 5. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the public health law, in relation to requiring a utilization review agent to follow certain rules when establishing a step therapy protocol

Purpose or general idea of bill

The purpose of this bill is to require certain patient protections for plans and utilization review agents to follow when establishing a step therapy protocol.

Summary of provisions

Section one amends section 4902 of the insurance law by adding two new paragraphs (14) and (15) that require a utilization review agent, when they are establishing a step therapy protocol, to ensure various proto- cols. These include prohibiting a prescription drug that has not been approved by the US FDA from being within a step therapy protocol. In addition, a protocol cannot require an insured to try and fail on more than one drug before providing coverage to the insured. A protocol cannot require the use of a step therapy-required drug for longer than 30 days.

Section one also states that a protocol cannot be imposed on an insured if they have taken the prescribed drug covered by a plan within the past 365 days. In addition, a step therapy protocol cannot require a newly enrolled insured to repeat step therapy for a prescribed drug where they have already completed a step therapy protocol for that drug under a different plan. Finally, a protocol cannot impose on an insured a prescribed drug that was previously approved by a plan for a specific medical condition after the insured's plan implements a formulary change.

This section also requires a utilization review agent to ensure that the protocol accepts any attestation submitted by the insured's health care professional stating that a required drug has failed.

Section two amends section 4903 of the insurance law to add that any approval of a step therapy protocol override determination request must be honored until 12 months after the date of approval or renewal of the plan.

Section two also states that if a utilization review agent fails to comply with any of the step therapy protocol requirements it will be considered as a basis for granting an override of that step therapy protocol.

Section three amends section 4902 of the public health law with the same requirements as section one.

Section four amends section 4903 of the public health law with the same requirements as section two.

Section five requires that this act shall take effect immediately.

Justification

These additional patient protections are intended to ensure that patients do not need to try and fail repeatedly on inappropriate medica- tions and that step therapy protocols to do not cause significant delays in access to the prescribed medication. Step therapy protocols that ignore prior failures or cause long delays can result in adverse events, including disease progression and relapse.

Prior legislative history

New Bill

Fiscal implications

None

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.